Ask the doctor: What do you know about Prolia and Reclast for osteoporosis?
All three drugs suppress bone remodeling, increase bone density, and reduce the risk of fractures. Denosumab and zoledronic acid reduce fractures at both the spine and hip, but ibandronate reduces only spine fractures. Consequently, clinicians recommend ibandronate less often than two other bisphosphonates — alendronate (Fosamax) and risedronate (Actonel).
To continue reading this article, you must log in.
Source matters. Subscribe to HarvardHealthOnline+ FREE for 30 days for unlimited access to the site – where all content is reviewed by an HMS physician or faculty expert.
With HHO+ you get these exclusive benefits:
- Unlimited access to all Harvard Health Online content
- 4 expertly curated newsletters delivered monthly
- Customized website experience aligned to your health goals
- In-depth health guides on topics like sleep, exercise, and more
- Interactive features like videos and quizzes
- Members-only access to exclusive articles and resources
SPECIAL OFFER! UNLOCK EXPERT ACCESS for 30 days FREE!
Sign Me UpAlready a member? Login ».
Disclaimer:
As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles.
No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.
